Showing papers in "Journal of Crohn's and Colitis in 2009"

TL;DR: The treatment of inflammatory bowel disease has been revolutionised over the past decade by the increasing use of immunomodulators, mainly azathioprine/6-mercaptopurine and methotrexate, together with the advent of biological therapy.

TL;DR: Overall abdominal symptoms, abdominal pain, bloating, wind and diarrhoea improved in patients with Crohn's disease and ulcerative colitis, and reduction of FODMAP intake offers an efficacious strategy for patients with IBD who have concurrent functional gut symptoms.

TL;DR: A significant rise in Clostridium difficile-associated diarrhea was observed in both IBD and non-IBD patients, and the clinical outcome was favorable with only one IBD patient needing semi-urgent colectomy.

TL;DR: Intervention studies are required to clarify whether IC represents an IBD phenotype associated with childhood disease onset or whether the high IC frequency is due to difficulties in establishing a UC or CD diagnosis.

TL;DR: The results, from the South Limburg region (the Netherlands), show no significant change in incidence rates of IBD, and the incidence found is relatively high compared to other European countries.

TL;DR: In AZA/ 6-MP non-responders with increased 6-MMP/6-TGN ratios, addition of allopurinol continues to demonstrate safety and efficacy for long-term maintenance and steroid-sparing in IBD.

TL;DR: The increased concordance and relapse rate in familial UC, might point to a larger genetic component in UC than previously suggested, confirmed the importance of genetic influence on the development of CD.

TL;DR: Some basic guidelines about how to prescribe physical exercise in Crohn's disease can be provided, however, more research is needed as few studies have been carried out so far.

TL;DR: The fascinating history of Salazopyrin and salicylates is described from the first serendipitous observations to the last randomized clinical trials and the possible use of mesalazine in the prevention of colorectal cancer was reviewed.

TL;DR: Results provide a mechanistic rationale for both the failure of lenalidomide in a recent randomised controlled trial in Crohn's disease, and for the evaluation of CC-10004 as a novel oral therapy in the treatment of CD and UC.

TL;DR: Infliximab therapy is effective for maintenance of clinical remission and mucosal healing in patients with steroid-dependent UC.

TL;DR: In patients with inflammatory bowel disease apoptotic phenomena involve both enteric neurons and enteroglial cells, and may play a role in the abnormalities of the enteric nervous system.

TL;DR: Antibiotics, azathioprine/6-mercaptopurine and conservative surgery are the mainstay of therapy for fistulizing Crohn's disease and infliximab is a therapeutic option in patients without prior response to immunosuppressant therapy.

TL;DR: A 55-year old man with Crohn's disease who developed retrobulbar optic neuritis of the left eye after the infusion of infliximab is described, which underscores the clinical awareness of the possible association, especially in light of the increasing use of this cytokine inhibitor.

TL;DR: This is a rare case of totally reversible bilateral optic neuritis associated with multiple sclerosis in a patient with Crohn's disease and sacroiliitis receiving also Infliximab induction therapy.

TL;DR: Nkx2-3 is genetically associated with CD and is up-regulated in CD, suggesting that Nkx 2- 3 is involved in the pathogenesis of CD.

TL;DR: A case of Crohn's disease with pulmonary extra-intestinal manifestation (bronchiolitis obliterans organizing pneumonia-like changes) treated with infliximab and an overview of cases of inflammatory bowel disease with lung involvement, treated with tumor necrosis factor-α antagonists is presented.

TL;DR: It is reported for the first time the successful usage of infliximab in treating Crohn's disease in an HIV positive patient who is not on any anti-retroviral treatment.

TL;DR: Marked fatigue is a previously unrecognized adverse effect of thiopurines that does not appear to be drug-specific and its onset might be masked by concurrent steroid therapy.

TL;DR: Thiopurine analogs, methotrexate and anti-TNFs are favoured in ST-D patients and ST-R patients and remain the first-line therapy for active luminal CD.

TL;DR: This is the first study on public awareness of the terms "Crohn's disease" and "ulcerative colitis" and poor knowledge in the public is reported which may vastly impact outcome and health economic consequences of IBD.

TL;DR: A case of a patient with ulcerative colitis, exhibiting a non-toxic megacolon, resulting from a double transverse and sigmoid volvulus probably stemming from congenital dolichocolon, is being presented here, stressing the importance of prompt differential diagnosis.

TL;DR: The key aspects of an 'ideal' IBD consultation and main considerations when talking about the impact of IBD on patients' daily lives are described, which can serve as a framework for developing practical tools to help facilitate IBD patient-physician communication.

TL;DR: A 45-year old woman diagnosed ten years ago with ulcerative pancolitis and primary sclerosing cholangitis was referred to the outpatient IBD clinic because of xerostomy but not for xerophthalmy for the previous three months and was diagnosed with Sjogren's syndrome.

TL;DR: Par-2 is up-regulated on ileal mucosal mast cells in Crohn's ileitis, possibly due to the action of inflammatory cytokines, such as TNF-α, which may contribute to perpetuating the inflammatory process in the intestinal mucosa in Cro bowel disease.

TL;DR: The mosaic pattern in the colorectal mucosa of patients studied due to chronic diarrhea could be a distinguishing feature of collagenous colitis.

TL;DR: The low clinical and surgical recurrence rate in the neoterminal ileum may suggest a protective effect of the neosphincter on postoperative recurrence of Crohn's disease.

TL;DR: The case of liver inflammatory pseudotumor occurring in the course of Crohn's disease in a 23-year-old woman and treated conservatively is reported.

TL;DR: This case demonstrates that very low dose 6-TG under close clinical surveillance and frequent therapeutic drug monitoring, may be a rescue drug for IBD-patients with low or without functional TPMT activity.